Adipocyte differentiation defect in mesenchymal stromal cells of patients with malignant infantile osteopetrosis

Uçkan, Duygu; Kılıç, Emine; Sharafi, Parisa; Kazik, M. H.; Aerts‐Kaya, Fatima; Erdemlı, Esra; Can, Alp; Tezcaner, Ayşen; Kocaefe, Çetin

doi:10.1080/14653240802582083

Cited by 25 publications

(20 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analyses were performed with P3 cells. hBM-MSCs were confirmed to be negative for hematopoietic markers by flow cytometry and capable of differentiating into osteocytes and adipocytes in vitro (18).…”

Section: Methodsmentioning

confidence: 96%

“…Control and labeled (50 g/mL iron and 0.375 g/mL poly-L-lysine for 48 h) MSCs were grown to confluency (90 -100%) on six-well plates, then, exposed to adipogenic medium consisting of LG-DMEM supplemented with 10% FBS, 1 M dexamethasone, 60 M indomethacin, 500 M isobutylmethylxanthine, and 5 g/mL insulin (Sigma Chemical Co.-Aldrich) for 21 d and stained with Oil Red O (Sigma Chemical Co.-Aldrich; Fig. 1B) (18).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal Stem Cell Therapy in Necrotizing Enterocolitis: A Rat Study

et al. 2011

View full text Add to dashboard Cite

ABSTRACT:We evaluated the potential therapeutic use of exogenous human bone marrow-derived mesenchymal stem cells (hBMMSCs) in an experimental rat model of necrotizing enterocolitis (NEC). Thirty-six newborn Sprague-Dawley rats were randomly divided into three groups: NEC, NEC ϩ hBM-MSC, and a control (control and control ϩ hBM-MSC). NEC was induced by enteral formula feeding, exposure to hypoxia-hyperoxia, and cold stress. After NEC was induced, iron-labeled hBM-MSCs were administered by intraperitoneal injection. All pups were killed on the fourth day following injection, and the terminal ileum was excised for a histopathological and immunohistochemical evaluation. The pups in the NEC ϩ hBM-MSC group showed significant weight gains and improvements in their clinical sickness scores (p Ͻ 0.01). Bowel damage severity observed in the histopathological evaluation was significantly lower in the NEC ϩ hBM-MSC group than that in the NEC group (p ϭ 0.012). The number of MSCs homing to the bowel was significantly higher in the NEC ϩ hBM-MSC group than that in the control ϩ hBM-MSC group. In conclusion, this is the first study that has evaluated the effectiveness of hBM-MSCs in a neonatal rat NEC model. MSCs reduced histopathological damage significantly. (Pediatr Res 70: 489-494, 2011) N ecrotizing enterocolitis (NEC) is the most common gastrointestinal emergency and a leading cause of mortality and morbidity in newborn infants. The etiology and pathophysiology of NEC remains unclear. Although prematurity is the most consistent risk factor, hypoxic-ischemic injury, formula feeding, abnormal bacterial colonization, antenatal and postnatal risk components, and genetic aspects comprise other potential risk factors (1-3). Medical management of severe cases is often inadequate, and surgical intervention may be warranted. Thus, ϳ20 -40% of neonates eventually require a surgical procedure (1,4,5). In addition, morbid sequelae among survivors include impaired growth, short bowel syndrome, prolonged neonatal hospitalization, and poor longterm neurodevelopment (1-5). Therefore, the introduction of new strategies for the prevention and/or therapy for this devastating disease is essential to increase the survival rate and to reduce significant complications.Mesenchymal stem cells (MSCs) are multipotent cells capable of differentiating into multiple cell types. In addition, MSCs secrete a wide variety of cytokines and chemokines that have beneficial paracrine actions during tissue repair (6 -11). Because of these unique properties, MSCs could be a future option for treating various diseases. Studies on the potential use of stem cells in pediatric diseases have recently aroused interest among clinicians (12-15), although stem cell therapy has not yet been studied as a treatment modality for neonatal intestinal disorders such as NEC. In this study, the therapeutic potential of exogenous human bone marrow-derived (hBM)-MSC therapy was evaluated in an experimental neonatal rat model of NEC. MATERIALS AND METHODSAnimal model. Fatih Uni...

show abstract

Section: Methodsmentioning

confidence: 96%

Section: Methodsmentioning

confidence: 99%

Mesenchymal Stem Cell Therapy in Necrotizing Enterocolitis: A Rat Study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Se obtuvo el consentimiento informado de los padres y se utilizaron 2 ml de médula ósea. Se llevaron a cabo ensayos de diferenciación y se determinaron los perfiles inmunofenotípicos para caracterizar las hBM-MSC 22,23 …”

Section: Aislamiento Y Cultivo De Hbm-mscunclassified

Efecto aditivo de las células madre mesenquimales y del defibrótido en un modelo de trombosis arterial en ratas

Díllí

Kılıç

Yumuşak³

et al. 2017

Arch Argent Pediat

View full text Add to dashboard Cite

“…Culture expanded control and labeled (50 µg/mL iron and 0.375 g/ mL poly-L-lysine for 48 h) hBM-MSCs were immunophenotypically characterized by flow cytometry (Becton Dickinson FACS Aria; BD Biosciences, Sparks, MD). 22 Tissue harvesting R a t s w e r e s a c r i f i c e d 7 d a y s a f t e r t h e 2 nd injection, after anesthetized with ketamine/ xylazine. The left groin was opened and femoral artery was dissected.…”

Section: Isolation and Culture Of Hbm-mscsmentioning

confidence: 99%

“…An informed consent was obtained from the parents and 2 ml of bone marrow was used. Differentiation assays and immunophenotypic profiling were performed for characterization of hBM-MSCs [22,23] ( Figure 1A-B).…”

Section: Isolation and Culture Of Hbm-mscsmentioning

confidence: 99%

Additive effect of mesenchymal stem cells and defibrotide in an arterial rat thrombosis model

et al. 2017

View full text Add to dashboard Cite

Background/aim. In this study, we aimed to investigate the additive effect of mesenchymal stem cells (MSC) and defibrotide (DFT) in a rat model of femoral arterial thrombosis. Methods. Thirty Sprague Dawley rats were included. An arterial thrombosis model by ferric chloride (FeCl3) was developed in the left femoral artery. The rats were equally assigned to 5 groups: Group 1-Sham-operated (without arterial injury); Group 2-Phosphate buffered saline (PBS) injected; Group 3-MSC; Group 4-DFT; Group 5-MSC + DFT. All had two intraperitoneal injections of 0.5 ml: the 1 st injection was 4 h after the procedure and the 2 nd one 48 h after the 1 st injection. The rats were sacrificed 7 days after the 2 nd injection. Results. Although the use of human bone marrow-derived (hBM) hBM-MSC or DFT alone enabled partial resolution of the thrombus, combining them resulted in near-complete resolution. Neovascularization was two-fold better in hBM-MSC + DFT treated rats (11.6 ± 2.4 channels) compared with the hBM-MSC (3.8 ± 2.7 channels) and DFT groups (5.5 ± 1.8 channels) (P < 0.0001 and P= 0.002, respectively). Conclusion. The combined use of hBM-MSC and DFT in a rat model of arterial thrombosis showed additive effect resulting in near-complete resolution of the thrombus.

show abstract

Adipocyte differentiation defect in mesenchymal stromal cells of patients with malignant infantile osteopetrosis

Cited by 25 publications

References 33 publications

Mesenchymal Stem Cell Therapy in Necrotizing Enterocolitis: A Rat Study

Mesenchymal Stem Cell Therapy in Necrotizing Enterocolitis: A Rat Study

Efecto aditivo de las células madre mesenquimales y del defibrótido en un modelo de trombosis arterial en ratas

Additive effect of mesenchymal stem cells and defibrotide in an arterial rat thrombosis model

Contact Info

Product

Resources

About